Sustained stimulation of vasopressin and oxytocin release by ATP and phenylephrine requires recruitment of desensitization-resistant P2X purinergic receptors

Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R940-9. doi: 10.1152/ajpregu.00358.2009. Epub 2009 Jul 22.

Abstract

Coexposure of hypothalamo-neurohypophyseal system explants to ATP and phenylephrine [PE; an alpha1-adrenergic receptor (alpha1-AR) agonist] induces an extended elevation in vasopressin and oxytocin (VP/OT) release. New evidence is presented that this extended response is mediated by recruitment of desensitization-resistant ionotropic purinergic receptor subtypes (P2X-Rs): 1) Antagonists of the P2X2/3 and P2X7-Rs truncated the sustained VP/OT release induced by ATP+PE but did not alter the transient response to ATP alone. 2) The P2X2/3 and P2X7-R antagonists did not alter either ATP or ATP+PE-induced increases in [Ca(2+)](i). 3) P2X2/3 and P2X7-R agonists failed to elevate [Ca(2+)](i), while ATP-gamma-S, an agonist for P2X2-Rs increased [Ca(2+)](i) and induced a transient increase in VP/OT release. 4) A P2Y1-R antagonist did not prevent initiation of the synergistic, sustained stimulation of VP/OT release by ATP+PE but did reduce its duration. Thus, the desensitization-resistant P2X2/3 and P2X7-R subtypes are required for the sustained, synergistic hormone response to ATP+PE, while P2X2-Rs are responsible for the initial activation of Ca(2+)-influx by ATP and ATP stimulation of VP/OT release. Immunohistochemistry, coimmunoprecipitation, and Western blot analysis confirmed the presence of P2X2 and P2X3, P2X2/3, and P2X7-R protein, respectively in SON. These findings support the hypothesis that concurrent activation of P2X2-R and alpha1-AR induces calcium-driven recruitment of P2X2/3 and 7-Rs, allowing sustained activation of a homeostatic circuit. Recruitment of these receptors may provide sustained release of VP during dehydration and may be important for preventing hemorrhagic and septic shock.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / analogs & derivatives
  • Adenosine Triphosphate / metabolism*
  • Adenosine Triphosphate / pharmacology
  • Adrenergic alpha-1 Receptor Agonists*
  • Adrenergic alpha-Agonists / pharmacology*
  • Animals
  • Blotting, Western
  • Calcium / metabolism
  • Hypothalamo-Hypophyseal System / drug effects*
  • Hypothalamo-Hypophyseal System / metabolism*
  • Immunohistochemistry
  • Immunoprecipitation
  • In Vitro Techniques
  • Male
  • Microscopy, Fluorescence
  • Oxytocin / metabolism*
  • Perfusion
  • Phenylephrine / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-1 / metabolism
  • Receptors, Purinergic P2 / drug effects
  • Receptors, Purinergic P2 / metabolism*
  • Receptors, Purinergic P2X2
  • Receptors, Purinergic P2X3
  • Receptors, Purinergic P2X7
  • Receptors, Purinergic P2Y1
  • Signal Transduction / drug effects
  • Time Factors
  • Vasopressins / metabolism*

Substances

  • Adrenergic alpha-1 Receptor Agonists
  • Adrenergic alpha-Agonists
  • Receptors, Adrenergic, alpha-1
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2X2
  • Receptors, Purinergic P2X3
  • Receptors, Purinergic P2X7
  • Receptors, Purinergic P2Y1
  • Vasopressins
  • Phenylephrine
  • adenosine 5'-O-(3-thiotriphosphate)
  • Oxytocin
  • Adenosine Triphosphate
  • alpha,beta-methyleneadenosine 5'-triphosphate
  • Calcium